FPOLayout for review — draft content, for placement only. Imagery and claims shown from global material pending Canadian adaptation. Ghosted items show the future full website.
PrFREHEMGO®denecimig injectionMy profileFPOENFR

FREHEMGO® has a proven safety profile1–5

FREHEMGO® has a proven safety profile with no safety concerns reported, and almost no injection pain.*,**1–5 FPO

No thromboembolic events

No events reported, including no arterial or venous thrombotic events, or thrombotic microangiopathies1–5

No disruption for surgery

No surgeries or procedures required discontinuation of FREHEMGO®1–5

No neutralising antibodies

No clinical evidence of neutralising antibodies1–5

FREHEMGO® was well tolerated across clinical trials1

Pooled safety data from 448 participants across three Phase III clinical studies1

ADRs reported in ≥1% of patients from pooled clinical trials FPO table styling for placement only — final design per eCVA
Adverse drug reaction (ADR)Number of patients (N=448) n (%)
Injection site reaction (ISR)*54 (12.1%)
Prothrombin fragment 1.2 increased43 (9.6%)verify — source PPT reads 4.3
Fibrin D-dimer increased9 (2.0%)

The safety profile was similar between children, adolescents, and adult participants FPO

The AE table / ISR information from screen 4.2 of the eCVA will also be presented here. FPO

View more

TG chartFPO

Normal levels all month long

Learn how FREHEMGO® normalises thrombin generation all month long.

Discover the innovation
Study imageryFPO

The freedom of zero bleeds

Discover powerful protection at every stage of the hemophilia journey.

Explore efficacy data
Pen line-upFPO

Dosing made simple

No mg/kg dosing. No dose calculations — 5 prefilled pens.

Discover dosing